Dr. Jeffrey R. Jay, M.D.
@Great Point Partners Llc
Latest period2024 - Q3ReportedManaged Assets$339.762MTotal holdings29
Assets growth rate-34.91%Assets growth rate (2-Q avg)-26.77%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Great Point Partners Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 29 positions.
Assets under management
The assets under management (AUM) of Great Point Partners Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 339.762M in assets, with a quarterly growth rate of -34.91% and a 2-quarter average growth rate of -26.77%. The portfolio is managed by Dr. Jeffrey R. Jay, M.D., and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
INSMInsmed Inc
| 0% | $16.75M 250,000 shares@ $67.0 avg price | Exited |
FOLDAmicus Therapeutics Inc
| 0% | $14.835M 1.496M shares@ $9.92 avg price | Exited |
ESPREsperion Therapeutics Inc Ne
| 0% | $12.857M 5.792M shares@ $2.23 avg price | Exited |
TERNTerns Pharmaceuticals Inc
| 0% | $7.827M 1.149M shares@ $6.82 avg price | Exited |
PBYIPuma Biotechnology Inc
| 0% | $4.846M 1.487M shares@ $3.26 avg price | Exited |
KYTXKyverna Therapeutics Inc
| 0% | $3.744M 499,152 shares@ $7.5 avg price | Exited |
SYRESpyre Therapeutics Inc
| 0% | $3.165M 134,612 shares@ $23.51 avg price | Exited |
ANABAnaptysbio Inc
| 0% | $626,500 25,000 shares@ $25.06 avg price | Exited |
LXRXLexicon Pharmaceuticals Inc
| 0% | $50,400 30,000 shares@ $1.68 avg price | Exited |